Stock IVBIY INNOVENT BIOLOGICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Innovent Biologics, Inc. OTC Markets

Equities

IVBIY

US45783L1017

Market Closed - OTC Markets
Other stock markets
 19:13:26 26/06/2024 BST 		5-day change 1st Jan Change
19.68 USD +0.92% Intraday chart for Innovent Biologics, Inc. -0.35% -5.79%
06-25 Novo Nordisk's Wegovy Weight-Loss Drug Gets Approval in China DJ
06-25 Innovent Biologics, Inc. Presents the Results of the First Phase 3 Study of Mazdutide for Weight Management at the ADA's 84th Scientific Sessions CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Innovent Biologics, Inc. Presents the Results of the First Phase 3 Study of Mazdutide for Weight Management at the ADA's 84th Scientific Sessions
Innovent Biologics, Inc Receives Fast Track Designation from the U.S. FDA for IBI343 (TOPO1i anti-CLDN18.2 ADC) as Monotherapy for Advanced Pancreatic Cancer
Innovent Biologics, Inc. Presents at 2024 ASCO Annual Meeting on Clinical Data of Anti-CLDN18.2 ADC in Patients with Advanced Pancreatic Cancer or Biliary Tract Cancer
Innovent Biologics, Inc. Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib (ROS1 Inhibitor) Publishes in JCO and Reports at 2024 ASCO Annual Meeting
Innovent Biologics, Inc. Presents Phase 1 Clinical Data of First-In-Class PD-1/IL-2a Bispecific Antibody Fusion Protein in Melanoma, Colorectal Cancer and Other Solid Tumors at 2024 ASCO Annual Meeting
Innovent Biologics, Inc. Announces Picankibart Achieved Primary Endpoints in A Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to the NDA to the NMPA
Chinese Regulator Accepts Innovent Biologics' New Drug Application for Thyroid Eye Disease Drug
Innovent Biologics Announces National Medical Products Administration of China Accepts the New Drug Application for IBI311
Innovent Receives NMPA Breakthrough Therapy Designation for IBI343(Anti-Claudin18.2 ADC) as Monotherapy for Advanced Gastric Cancer
Innovent Biologics, Inc. Announces Board and Committee Changes
Innovent Biologics, Inc. Appoints Samuel Zhang as Global Chief Business Officer
Innovent Appoints Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer
Hutchmed endometrial cancer treatment application accepted for review
HSBC in special payout on Canada sale; Astra FDA win
Innovent Biologics New Cancer Drug Gets NDA from Chinese Authority
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status
Innovent Biologics, Inc. Announces the National Medical Products Administration Accepts the New Drug Application
Innovent Biologics' Loss Narrows in 2023 as Revenue Grows
Innovent Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Innovent Biologics, Inc. Releases the Results of Two Clinical Studies of Ibi311 (An Anti-IGF-1R Monoclonal Antibody) in Oral Presentations At the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 1801 Stock
  4. IVBIY Stock
  5. News Innovent Biologics, Inc.
  6. Other languages